An Open Study of the Safety, Tolerability and Immunogenicity of "Gam-COVID-Vac Lyo" Vaccine Against COVID-19

Preventive Immunization COVID-19 Clinical Trial

Official title:

An Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac Lyo" Lyophilizate for the Preparation of a Solution for Intramuscular Injection With the Participation of Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04437875
• Other study ID #: 03-Gam-COVID-Vac Lyo-2020
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: June 17, 2020
• Est. completion date: August 10, 2020

Study information

• Verified date: June 2020
• Source: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

the purpose of this study: to evaluate the safety, tolerability and immunogenicity of the drug "Gam-COVID-Vac Lyo", a lyofilizate for preparing solution for intramuscular administration, at various times after vaccination in healthy adult volunteers.

Description:

An open two stage non-randomized Phase 1 study with the participation of healthy volunteers. This clinical trial is an open study of safety, tolerability and immunogenicity of the drug "Gam-COVID-Vac Lyo", lyophilisate for the preparation of a solution for intramuscular administration, with the participation of healthy volunteers.

Study objectives

1. A safety and tolerability assessment of the drug "Gam-COVID-Vac Lyo", lyophilisate for the preparation of a solution for intramuscular administration, using single dose of each component (Stage 1).

2. A safety and tolerability assessment of the drug "Gam-COVID-Vac Lyo", lyophilisate for the preparation of a solution for intramuscular administration, using prime-boost immunization according to the proposed scheme (Stage 2).

Study Design Stage 1 the First group, 9 volunteers, will receive the drug, a solution for intramuscular administration, in the mode of single immunization with component 1 in a full therapeutic dose.

the Second group, 9 volunteers, will receive the drug, a solution for intramuscular administration, in the mode of single immunization with component 2 in the full therapeutic dose.

The studied drugs will be administered to a total of 18 volunteers in a hospital setting and after administration, the drug's safety will be continuously monitored for 5 days. Based on the results of the safety assessment, the Chief investigator decides to proceed to the second stage of the study on the 5th day after the introduction of the studied drugs.

Second stage The second stage will include 20 volunteers and three understudies. Volunteers of the second stage will be vaccinated no earlier than 5 days after vaccination of participants of the first stage.

Volunteers participating in the second stage of the study (a total of 20 people) will receive the study drug according to the booster scheme: the introduction of component 1 will be carried out on day 1, and component 2-on the 21st day of the study. Follow-up will be carried out during 4 visits: on 7, 14, 28, 42 days after administration of the drug.

Throughout the inpatient observation and the follow-up period (180 days) of visits during the entire study, safety information will be collected

Recruitment information / eligibility

• Status: Completed
• Enrollment: 38
• Est. completion date: August 10, 2020
• Est. primary completion date: August 3, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. males and females within the age range from 18 to 60 years;

2. written informed consent;

3. subject body mass index (BMI): 18.5 = BMI = 30;

4. negative PCR test results for SARS-CoV-2 (during the screening);

5. no history of COVID-2019 disease;

6. no contacts of volunteers with patients with COVID-2019 for at least 14 days;

7. negative test results for IgM and IgG antibodies to SARS-CoV-2;

8. subject agrees to use effective contraceptive methods during the entire period of participation in the study;

9. absence of acute infectious diseases at the time of vaccine administration and 14 days before vaccination;

10. negative pregnancy test of blood or urine (for women of childbearing age);

11. subject has negative tests for HIV, hepatitis B and ?, syphilis or confirmed medical history;

12. subject has a negative result of the urine test for residual narcotic drugs;

13. negative test for alcohol in exhaled air;

14. the absence of malignant diseases of any nature and localization;

15. in medical history and based on the screening results, subject has no diseases or pathologies of the gastrointestinal system, liver, kidneys, cardiovascular system and blood, CNS, musculoskeletal system, urogenital, immune and endocrine systems that from the point of view of the researcher and/or of the organizer of the study, may affect the safety of the volunteer and the evaluation of the study results (clinical, instrumental and laboratory tests did not reveal diseases or clinically significant deviations)

Exclusion Criteria:

1. volunteer involvement in another study over the last 90 days;

2. any vaccination over the last 30 days;

3. history of COVID-2019 disease;

4. positive PCR test results for SARS-CoV-2 (during the screening);

5. positive test results for IgM and IgG antibodies to SARS-CoV-2;

6. health staff in contact with people with COVID-2019;

7. respiratory symptoms in the last 14 days;

8. the administration of immunoglobulins or other blood products in the last 3 months;

9. regular current or past use of narcotic drugs;

10. subject has received immunosuppressive and/or immunomodulating agents within 6 months before the start of the study;

11. pregnancy or breast feeding;

12. exacerbation of allergic diseases at the time of vaccination;

13. subject has systolic blood pressure less than 100 mm Hg or greater than 139 mm Hg; diastolic blood pressure less than 60 mm Hg or greater than 90 mm Hg; heart rate lower than 60 beats per minute or above 100 beats per minute;

14. a burdened allergic history (anaphylactic shock, Quincke's edema, polymorphic exudative eczema, atopy, a history of serum sickness, hypersensitivity or allergic reactions to the introduction of any vaccines in history, known allergic reactions to vaccine components, etc.);

15. a history of autoimmune diseases in the volunteer's medical history and in relatives' medical history of the 1-2 degree of kinship;

16. subject smokes more than 10 cigarettes per day;

17. alcohol intake exceeding the low-risk level: no more than 20 grams of pure alcohol per day, no more than 5 days a week, alcohol intake within 48 hours before the administration of the drug;

18. planned hospitalization and/or surgery during the period of participation in the study, as well as 4 weeks before the expected date of the administration of the drug;

19. the presence of an associated disease that may affect the assessment of the results of the study;

20. any conditions that, according to the researcher's doctor, may be a contraindication to the participation in the study.

Related Conditions & MeSH terms

• Preventive Immunization COVID-19

Intervention

Biological:
• Gam-COVID-Vac Lyo
adenoviral-based vaccine against SARS-CoV-2

Locations

Country	Name	City	State
Russian Federation	Sechenov First Moscow State Medical University	Moscow

Sponsors (2)

Lead Sponsor	Collaborator
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation	Acellena Contract Drug Research and Development

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The changing of antibody levels against the SARS-CoV-2 glycoprotein S at 42 days	Determination of antibody levels against the SARS-CoV-2 glycoprotein S measured by an ELISA vs. baseline values	at days 0, 14, 21, 28, 42
Primary	Number of Participants With Adverse Events	Determination of Number of Participants With Adverse Events	through the whole study, an average of 180 days
Secondary	The changing of virus neutralizing antibody titer	Determination of virus neutralizing antibody titer	at days 0, 14, 28, 42
Secondary	The changing of antigen-specific cellular immunity level	Determination of antigen-specific cellular immunity (specific T-cell immunity, in particular, IFN-gamma production or lymphoproliferation)	at days 0, 14, 28